Weaver C. Barksdale & Associates Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Accenture
ACN
|
+$2.23M |
| 2 |
Automatic Data Processing
ADP
|
+$2.14M |
| 3 |
Cardinal Health
CAH
|
+$193K |
| 4 |
General Dynamics
GD
|
+$142K |
| 5 |
AbbVie
ABBV
|
+$135K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alexandria Real Estate Equities
ARE
|
+$1.05M |
| 2 |
Truist Financial
TFC
|
+$927K |
| 3 |
Lockheed Martin
LMT
|
+$304K |
| 4 |
Gilead Sciences
GILD
|
+$109K |
| 5 |
AES
AES
|
+$81.1K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 21.5% |
| 2 | Healthcare | 14.65% |
| 3 | Industrials | 12.71% |
| 4 | Technology | 11.77% |
| 5 | Energy | 9.24% |
Similar funds
Weaver C. Barksdale & Associates's Q1 2026 Portfolio in Review
As of Q1 2026, Weaver C. Barksdale & Associates held 64 positions worth $105M, up 10% from $95.3M the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Weaver C. Barksdale & Associates deployed $7.18M of net new capital in Q1 2026, opening 2 new positions and adding to 53 existing holdings. Its largest new stake was Accenture: 9,590 shares worth $1.9M.
By sector, the portfolio is most concentrated in Financials at 21% of assets, down from 25% a quarter earlier, followed by Healthcare and Industrials.
On the sell side, the largest reduction was Lockheed Martin, an estimated $304K trimmed.
- Weaver C. Barksdale & Associates's largest Q1 2026 buy was Accenture: 9,590 shares worth $1.9M.
- Weaver C. Barksdale & Associates added most to Cardinal Health in Q1 2026, an estimated $193K increase.
- Weaver C. Barksdale & Associates's biggest Q1 2026 reduction was Lockheed Martin, cutting an estimated $304K.
- Weaver C. Barksdale & Associates fully exited Alexandria Real Estate Equities in Q1 2026, selling an estimated $1.05M.
- Weaver C. Barksdale & Associates's ten largest holdings make up 21% of its $105M portfolio in Q1 2026.
- Weaver C. Barksdale & Associates opened 2 new positions and closed 2 in Q1 2026.
- Weaver C. Barksdale & Associates's portfolio value rose 10% quarter-over-quarter to $105M.
Based on Weaver C. Barksdale & Associates's 13F filing for Q1 2026, filed 14 May 2026.